Comparative Analysis of Therapeutic Effect Between Theranova Dialyzer and High Flux Dialyzer Using OMICS
- Conditions
- Diseases of the genitourinary system
- Registration Number
- KCT0004130
- Lead Sponsor
- Pusan National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
1. A person who have maintained hemodialysis for more than three months due to end stage kidney disease and have not changed their drug use for the past mont
2. A person whose hemodialysis access is not a catheter, who can maintain a blood flow rate of more than 250 ml/min
3. A person who have been provided with a description of all matters relating to the study and voluntarily signed and dated prior to participating in the study.
1. A person whose hemodialysis schedule is not three times per wee.
2. A person who peritoneal dialysis is also conducted with hemodialysis such as hybrid dialysis treatment.
3. A person receiving inpatient treatment to serious disease within the period studied.
4. A person who complain of a severe fluctuation of blood pressure and intractable fatigue during hemodialysis.
5. A person with frequent changes of dry weight and dialysis prescription
6. A persion who maintain dialysis with catheter
7. A person who can't measure blood pressure in upper arm.
8. A person with a malignant tumor history who has a symptom or who has not been diagnosed with a complete cure.
9. pregnant and breastfeeding targets
10. A person who participated in other clinical trials with interventional design.
11. A person who is not suitable for this study according to judgement of investigators
12. A person with vulnerable or limited ability to agree with this study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method proteomics (blood, dialysate);metabolomics (blood, dialysate)
- Secondary Outcome Measures
Name Time Method proteomics (dialysis membrane fiber);metabolomics (dialysis membrane fiber);clearance of middle molecules (a1-microglobulin, fetuin A, Fibroblast growth factor-23)